Myriad Genetics (MYGN) Misses Q4 EPS by 6c, Guidance Misses Consensus
Tweet Send to a Friend
Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.41, $0.06 worse than the analyst estimate of $0.47. Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
